type a plus sign (+) inside this box Approval for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number **Application Number** 09/965,631 TRANSMITTAL **Filing Date** 09/27/01 **FORM First Named Inventor** Friddle Group Art Unit 1645 (to be used for all correspondence after initial filing) **Examiner Name** To be assigned Total Number of Pages in This Submission 15 Attorney Docket Number LEX-0241-USA ENCLOSURES (check all that apply) Assignment Papers After Allowance Communication Fee Transmittal Form (for an Application) to Group Appeal Communication to Board Fee Attached Drawing(s) of Appeals and Interferences Appeal Communication to Group Amendment / Reply Licensing-related Papers (Appeal Notice, Brief, Reply Brief) After Final Petition Proprietary Information Petition to Convert to a Affidavits/declaration(s) Status Letter Provisional Application Power of Attorney, Revocation Other Enclosure(s) (please Extension of Time Request Change of Correspondence Address identify below): return postcard Express Abandonment Request Terminal Disclaimer PTO Form 1449 and 17 references International Search Report Supplemental Information Request for Refund Disclosure Statement Certified Copy of Priority CD, Number of CD(s) Document(s) Remarks Response to Missing Parts/ Incomplete Application Response to Missing Parts 24231 under 37 CFR 1.52 or 1.53 PATENT TRADEMARK OFFICE SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Lance K. Ishimoto Reg. No. 41,866 Individual name Lexicon Genetics Incorporated Lance K. John on by Devil W. Leben pa. No. 41,071 Signature Date March 3, 2003 CERTIFICATE OF MAILING

## I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Box DD, P.O. Box 2327, Arlington, VA 22202 on this date: Typed or printed name Nancy Stacey Date March 3, 2003

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents. Washington, DC 20231.

## MAR 0 6 2003 E IN THE UNITED STATES PATENT AND TRADEMARK OFFICE Appleant(s): Friddle et al.

Application No.: 09/965,631

Filed: 09/27/01

Title: Novel Human Proteases and

Polynucleotides Encoding the Same

Attorney Docket No.: LEX-0241-USA

Group Art Unit: 1645

Examiner: To Be Assigned

Commissioner for Patents Washington, D.C. 20231

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Supplemental Information Disclosure Statement is submitted:

 (Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)
 under 37 CFR 1.97(c) together with either a:  Certification under 37 CFR 1.97(e), or  a \$180.00 fee under 37 CFR 1.17(p), or  (After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
 under 37 CFR 1.97(d) together with a:  Certification under 37 CFR 1.97(e), and a petition under 37 CFR 1.97(d)(2)(ii), and a \$130.00 petition fee set forth in 37 CFR 1.17(i)(1).  (Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

X Applicant(s) submit herewith Form PTO 1449-Supplemental Information Disclosure Citation together with copies, of patents, publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

The relevance of the attached references are that they were cited in a communication from a foreign patent office in a counterpart foreign application corresponding to the above-identified application.

Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

March 3, 2003

Date

Lance K. Solumito by Cavil N. Slove par no. 41,071

Lance K. Ishimoto Reg. No. 41,866

LEXICON GENETICS INCORPORATED (281) 863-3333

Z4ZJI
PATENT TRADEMARK OFFICE

To be assigned

LEX-0241-USA

Please type a plus sign (+) inside this box.  Under the Paperwork Reduction Act of 1999	F F F F F F F F F F F F F F F F F F F	Paten cond to a collection of information ur	PT( Approved for use through 10/31/99. t and Trademark Office; U.S. DEPARTMENT nless it displays a valid OMB control number.	٠,
Substitute for form 1449A/PTO	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~		Complete if Known	
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	MAR 0 6 2003	Application Numb r	09/965,631	_
SUPPLEM INFORMATION D	ENTAL 3	Filing Date	09/27/01	_
INFORMATION D	ISO ORBAF	First Named Inventor	Friddle	_
OTATELENT DV	ADDITOANT	Group Art Unit	1645	Ś

STATEMENT BY APPLICANT

Sheet

				LLC DATENT DOCUMENT	TE	<del></del>			
	U.S. PAIENI DOCUMENTS								
Examiner		Cite	U.S. Patent I		Name of Patentee or Applicant	Date of Publication of cited Document	Where Relevant O.		
nitials*			No.1	Number	Kind Code <sup>2</sup> ( <i>if known</i> )	of Cited Document	MM-DD-YYYY	Passages or Relevante Figures Appear	
		· · ·			}				
					<del>  </del>				
			<del></del>	<del></del>	<del> </del>				
	<del></del>	<del></del>		<del></del>	<del> </del>				
			<del></del>	<del></del>	<del> </del>				
		<del></del>	<del></del>		<del></del>				
			<del></del>		<del></del>				
		<del></del>	<del></del>		<del></del>				
			<del></del>		<del> </del>				
					<del></del>				
					<del></del>				
					<del> </del>				
					<del></del>				
l					<u> </u>				
					1				
					1				
					1				
	+		<del></del>		+				

**Examiner Name** 

Attorney Docket Number

	FOREIGN PATENT DOCUMENTS									
Examiner	Cite	Foreign Patent Document			Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant			
Initials*	No.1	• 1		Kind Code⁵ ( <i>if known</i> )	Applicant of Cited Document	cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	Te :		
	СК	wo	00/53774	A2	Neurocrine Biosciences, Inc.	09/14/00				
	CL	wo	01/34785	A1	Yamanouchi Pharmaceutical	05/17/01				
	СМ	wo	01/83782	A2	Sugen Inc.	11/08/01				
	CN	wo	01/98468	A2	Incyte Genomics, Inc.	12/27/01				

Examiner		Date	
Signature	,	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 195 uired to respond to a collection of information unless it displays a valid OMB control number Substitute for form 1449B/PT Complete if Known MAR 0 6 2003 Contraction of the Contraction o 09/965,631 SUPPLEMENTA **Application Number** Filing Dat 09/27/01 INFORMATION DISCL Friddle First Named Inv ntor STATEMENT BY APPLICANT Group Art Unit 1645 Examiner Name To be assigned Sheet 2 of 2 Attorney Docket Number LEX-0241-USA

Please type a plus sign (+) inside this box

			2.	_
		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	502	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	90	т
	СО	Database GENESEQ 'Online' "Human metalloproteinase ADAMTS-5 cDNA," 02/23/01, database accession no. AAA95831, XP002214186		
	СР	Database GENESEQ 'Online' "Rat metalloproteinase ADAMTS-5 cDNA," 02/23/01, database accession no. AAA95 XP002214187.	827,	
	CQ	Database GENESEQ 'Online' "Rat metalloproteinase ADAMTS-5," 02/23/01, database accession no. AAB21257, XP002214188.		
	CR	HURSKAINEN et al., "ADAM-TS5, ADAM-TS6, and ADAM-TS7, novel members of a new family of zinc metalloprot General features and genomic distribution of the Adam-TS family," Journal of Biological Chemistry, Vol. 274, No. 36 25555-25563, 09/03/99, XP002158991, ISSN: 0021-9258.	teases 6, pgs.	
	cs	TANG et al., "ADAMTS: A novel family of proteases with an ADAM protease domain and thrombospondin 1 repeats FEBS Letters, Elsevier Science Publishers, Vol. 445, No. 2-3, pgs. 223-225, 02/26/99, XP004259261, ISSN: 0014-5		
	СТ	ABBASZADE et al., "Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family," Journ Biological Chemistry, Vol. 274, No. 33, pgs. 23443-23450, 08/13/99, XP002937897, ISSN: 0021-9258.	nal of	
	C	Database GENESEQ 'Online' "Human metalloprotease MDTS6 cDNA," 08/23/01, database accession no. AAH410 XP002214189.	03,	
	CV	Database GENESEQ 'Online' "Human metalloprotease MDTS6 protein," 08/23/01, database accession no. AAG62: XP002214190.	299,	
	CW	Database GENESEQ 'Online' "Human metalloprotease partial DNA sequence #11," 02/26/02, database accession (AAS97182, XP002214191.	no.	
	СХ	Database GENESEQ 'Online' "Human metalloprotease partial protein sequence #11," 02/26/02, database accessio AAU72899, XP002214192.	n no.	
	CY	Database GENESEQ 'Online' "Human protease PRTS-11 cDNA sequence," 04/09/02, database accession no. ABK XP002214193.	(12894	,
	CZ	Database GENESEQ 'Online' "Human protease PRTS-11 protein sequence," 04/09/00, database accession no. AAU74751, XP002214194.		
	DA	CAL et al., "Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family metalloproteinases with disintegrin and thrombospondin-1 domains," GENE, Vol. 283, pgs. 49-62, 2002, XP002207 ISSN: 0378-1119.	of 625,	
		International Search Report, International Application No. PCT/US01/30350, 09/27/01 (Attorney Docket No. LEX-02 PCT)	241-	
				_
				_
				_
				_
				_

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.